Evidence map›Paper›PMID 35719018›Full record

ArticleEuropean journal of haematology2022

Early- and late-onset posttransplant lymphoproliferative disorders among adult kidney and liver transplant recipients.

Ranya Abdulovski, Dina L Møller, Andreas D Knudsen, Søren S Sørensen, Allan Rasmussen, Susanne D Nielsen, Neval E Wareham

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Heliyon · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ranya AbdulovskiViro-immunology Research Unit, Department of Infectious Diseases 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-9166-1012
Dina L MøllerViro-immunology Research Unit, Department of Infectious Diseases 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-3909-0643
Andreas D KnudsenViro-immunology Research Unit, Department of Infectious Diseases 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-5349-7829
Søren S SørensenDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-5898-8048
Allan RasmussenDepartment of Surgical Gastroenterology and Transplantation, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-9550-4767
Susanne D NielsenViro-immunology Research Unit, Department of Infectious Diseases 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-6391-7455
Neval E WarehamDepartment of Infectious Diseases, Rigshospitalet, Centre of Excellence for Health, Immunity, and Infections, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-5746-9385
University of Copenhagen · DK

Funding

Danish National Research foundation DNRF no 126Danmarks GrundforskningsfondNovo Nordic Foundation
6 · The paper itself

Abstract

objectivesPosttransplant lymphoproliferative disorder (PTLD) in solid organ transplant recipients has a high mortality and may present early (<2 years) or late (≥2 years) posttransplantation. We investigated the clinical characteristics of early and late PTLD among kidney and liver transplant recipients.

methodsRecipients, transplanted at Rigshospitalet, with PTLD development as adults from January 2010 to August 2020, were included. Clinical characteristics, laboratory parameters, and pathology of early and late PTLD were compared.

resultsThirty-one PTLD cases were detected where 10 (32%) were early and 21 (68%) were late PTLD. EBV DNA in plasma was detected in 78% versus 28% in early and late PTLD (p = .037). None of the recipients with early PTLD and nine recipients with late PTLD (47%) had Ann Arbor stage IV at the time of their diagnosis (p = .006). Cyclophosphamid-Hydroxyrubicin-Oncovin-Prednisolon was used for treatment in 10 (48%) recipients with late PTLD (p = 0.032) only. There was no difference in mortality between the two groups.

conclusionsRecipients with late PTLD had a lower prevalence of detectable EBV DNA in plasma, were diagnosed with more advanced disease, and were more frequently treated with chemotherapy compared to recipients with early PTLD.

Indexed as

Epstein-Barr Virus InfectionsLiver TransplantationLymphoproliferative DisordersAdultHumansIncidenceKidneyRetrospective StudiesRisk FactorsTransplant Recipientskidney transplantationliver transplantationposttransplant lymphoproliferative disordersolid organ transplantation

Identifiers

PMID35719018
PMCPMC9543731
OpenAlexW4283157022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.